Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resistin, an adipocytokine, offers protection against acute myocardial infarction.

Journal of molecular and cellular cardiology·2007
Same author

Liquid chromatographic analysis of phosphoamino acids at femtomole level using chemical derivatization with N-hydroxysuccinimidyl fluorescein-O-acetate.

Analytica chimica acta·2007
Same author

6-oxy-(acetyl piperazine) fluorescein as a new fluorescent labeling reagent for free fatty acids in serum using high-performance liquid chromatography.

Journal of chromatography. A·2007
Same author

Synthesis and fluorescence properties of 5,7-diphenylquinoline and 2,5,7-triphenylquinoline derived from m-terphenylamine.

Molecules (Basel, Switzerland)·2007
Same author

[Metabolic engineering of terpenoids in plants].

Sheng wu gong cheng xue bao = Chinese journal of biotechnology·2007
Same author

Hedgehog signaling in the murine melanoma microenvironment.

Angiogenesis·2007

Related Experiment Video

Updated: Apr 13, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K

[TKI Resistance for T790M Mutation].

Hong Wang1, Rui Guo1, Liyu Zhang1

  • 1Deputy Director of Lung Tumor Department, 307 Hospital, Beijing 100071, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|May 5, 2015
PubMed
Summary
This summary is machine-generated.

New EGFR inhibitors offer hope for non-small cell lung cancer (NSCLC) patients, overcoming resistance to earlier treatments. Research explores targeted therapies like afatinib and next-generation inhibitors for improved outcomes.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.4K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Related Experiment Videos

Last Updated: Apr 13, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.4K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Epidermal growth factor receptor (EGFR) inhibitors have revolutionized non-small cell lung cancer (NSCLC) treatment.
  • First-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib and erlotinib show initial efficacy but often lead to acquired resistance, frequently associated with the T790M mutation.
  • Irreversible EGFR-TKIs (afatinib, dacomitinib) and novel agents targeting resistance mutations represent advancements in NSCLC therapy.

Purpose of the Study:

  • To review the development and clinical significance of EGFR-TKIs in NSCLC.
  • To discuss the mechanisms of acquired resistance to first-generation EGFR-TKIs.
  • To evaluate the therapeutic potential of newer irreversible and targeted EGFR inhibitors.

Main Methods:

  • Review of existing literature on EGFR inhibitors in NSCLC.
  • Analysis of clinical trial data and resistance mechanisms.
  • Comparison of different generations of EGFR-TKIs based on binding kinetics and target scope.

Main Results:

  • First-generation EGFR-TKIs are effective but limited by resistance, with T790M mutations occurring in 50-60% of patients within a year.
  • Irreversible EGFR-TKIs (afatinib, dacomitinib) target multiple ErbB family receptors and show promise as first-line treatments.
  • Emerging EGFR inhibitors are specifically designed to overcome T790M resistance mutations.

Conclusions:

  • The evolution of EGFR-TKIs offers diverse treatment strategies for NSCLC patients.
  • Understanding the differences in EGFR-TKIs' targeting scope and binding is crucial for effective clinical application and combination therapy.
  • Continued development of targeted therapies is essential for improving long-term outcomes in NSCLC.